Slider with alias biomedical knowledge base not found.
Slider with alias covid 19 software 1 not found.
Slider with alias assays methods software 1 not found.
Slider with alias assays methods software 11 not found.
Network Pharmacology is an emerging field based in systems pharmacology that looks at the effect of drugs on both the interactome and the diseasome. The drug-target network (DTN) can play an important role in understanding the mechanisms of action of approved and experimental drugs. With a network-based insight, network pharmacology intends to systematically reflect and reveal the biological foundation of complex diseases and drug effects. The unique network-based relationship that drug pairs with Complementary Exposure to the disease module tend to be effective drug combinations is consistent with the non-overlapping pharmacological principle in rational drug combination design (Yıldırım et al., Nature biotech (Nature biotechnology (119–1126), 2007).
A disease or disorder is defined as rare when it affects fewer than 1 in 2000 people in Europe, and 1 in 1500 people in the US. There are over 6000 rare diseases affecting more than 400 million people globally, including 40 million in Europe and 30 million in the US. 95% of all rare diseases do not have a single approved drug treatment. 80% of these diseases have a genetic origin, and 50% of them affect children. 20% of all cancers are rare. 3-10% of all hospitalizations, regardless of age, are related to a rare disease. (Ref. Global Genes, Eurordis).
About Rare Diseases